Skip to main content

Table 1 Characteristics of patients with rheumatoid arthritis

From: Efficient delivery of the lncRNA LEF1-AS1 through the antibody LAIR-1 (CD305)-modified Zn-Adenine targets articular inflammation to enhance the treatment of rheumatoid arthritis

Patient

Age/sex

Body mass index (kg/m2)

Disease duration (years)

RF (IU/ml)

Anti-CCP (CU/ml)

ESR (mm/h)

CRP (mg/L)

1

54/M

25

1

1310

678.00

87

168.90

2

56/M

27.2

0.34

213

653.00

47

9.00

3

41/M

26.8

5

32.5

29.00

41

107.50

4

42/M

25.5

5

236

428.00

64

28.09

5

53/F

25.8

3

658

26.00

74

26.69

6

42/M

19.4

0.17

158

998.00

85

130.80

7

54/M

19.4

1

207

1082.00

116

53.13

8

51/F

26.7

4

496

894.00

44

15.50

9

39/F

18.8

0.42

125

2776.80

81

28.80

10

34/F

23.7

0.5

201

252.00

57

37.05

11

46/M

16.4

0.58

690

510.00

82

17.98

12

58/M

31.1

2

854

607.00

45

13.44

13

34/F

23.1

0.5

213

1195.00

31

2.50

14

53/F

29

2

554

2460.00

53

7.30

15

35/F

19.1

6

34.5

1022.60

28

2.60

16

53/F

22.5

1

24.5

749.50

75

15.70

17

53/M

29.1

2

1050

921.40

64

33.17

18

54/M

25.4

0.5

323

2776.80

46

67.66

19

52/F

23.1

3

1530

217.40

109

99.30

20

51/F

21.9

0.5

26.76

258.10

10

13.40

21

42/F

21.6

3

94.55

928.20

33

32.50

22

53/M

26

0.25

152.86

72.70

32

51.10

23

42/F

22.3

2

606

751.00

52

32.00

24

56/M

19.2

4

182

1496.60

37

10.40

  1. RF Rheumatoid factor, anti-CCP Cyclic citrullinated peptide antibody, ESR Erythrocyte sedimentation rate, CRP C-reactive protein